Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to ...

Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema: Berlin Tuesday, February 11, 2025, 10:00 Hrs [IST] Baye ...

Tampa General Hospital (TGH) today announced that Dr. Boris Naraev, a medical oncologist specializing in caring for patients living with gastrointestinal, neuroendocrine and endocrine tumors, has ...

Bayer submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea™ 8 mg (aflibercept 8 mg, ...

Diabetic retinopathy is a severe complication of diabetes that can lead to blindness. The Japanese clinical practice ...

The following is a summary of “Evaluating lipid-lowering drug targets for full-course diabetic retinopathy,” published in the ...

SNS Insider Reports: Retinal Surgery market to Grow at 6.05% CAGR, Fueled by Minimally Invasive Tools, Aging Population & Increasing diabetic Retinopathy Cases ...

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

It may cause mild side effects, such as abdominal pain, or more serious side effects, such as diabetic retinopathy. Keep reading to learn about the common, mild, and serious side effects that ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, recently announced it has completed its acquisition of Ambry Genetics, a ...